Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer

Inclusion Criteria: * Written informed consent and Health Insurance Portability and Accountability Act (HIPAA) authorization for release of personal health information * Must be age \>= 18 years * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 within 14 days prior to tissue consent * Absolute neutrophil count \> 1500/mcL (obtained within 14 days prior to vaccine administration) * Absolute lymphocyte count \>= 600 cells/µl (obtained within 14 days prior to vaccine administration) * Platelets \> 100,000 mm (obtained within 14 days prior to vaccine administration) * Hemoglobin \> 9.0 g/dL (obtained within 14 days prior to vaccine administration) (NOTE: The use of transfusion or other intervention to achieve hemoglobin \[Hgb\] \> 9.0g/dl is acceptable) * Serum creatinine =\< 1.5 x upper limit of normal (ULN) or calculated creatinine clearance \>= 60 mL/min using Cockcroft-Gault equation for patients with creatinine levels \> 1.5 x institutional ULN (obtained within 14 days prior to vaccine administration) * Total bilirubin =\< 1.5 x ULN OR direct bilirubin =\< 1 x ULN (obtained within 14 days prior to vaccine administration) * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =\< 2.5 x ULN unless liver metastases are present, in which case they must be =\< 5 x ULN (obtained within 14 days prior to vaccine administration) * Bilirubin =\< 1.5 X ULN (except in participants with documented Gilbert's disease, who must have a total bilirubin =…